Immunotherapy News and Research

Latest Immunotherapy News and Research

TxCell presents preclinical efficacy and tolerability data for Col-Treg at 2015 ARVO Annual Meeting

TxCell presents preclinical efficacy and tolerability data for Col-Treg at 2015 ARVO Annual Meeting

Keynote 24 study explores investigational approach to treating lung cancer

Keynote 24 study explores investigational approach to treating lung cancer

Novel combination therapy shows promise in mouse models of advanced prostate cancer

Novel combination therapy shows promise in mouse models of advanced prostate cancer

Sangamo BioSciences to present data on ZFP Therapeutic platform at ASGCT meeting

Sangamo BioSciences to present data on ZFP Therapeutic platform at ASGCT meeting

Special issue of Gastroenterology highlights how food impacts health and disease

Special issue of Gastroenterology highlights how food impacts health and disease

Oncologists publish review of advanced clinical treatments for pancreatic cancer

Oncologists publish review of advanced clinical treatments for pancreatic cancer

Astellas, Potenza collaborate to develop immuno-oncology therapeutics for patients with certain cancers

Astellas, Potenza collaborate to develop immuno-oncology therapeutics for patients with certain cancers

Novel approach allows real-time imaging of ongoing immune response

Novel approach allows real-time imaging of ongoing immune response

Experimental immune therapy generally safe, well-tolerated in women with triple-negative breast cancer

Experimental immune therapy generally safe, well-tolerated in women with triple-negative breast cancer

Immunocore reports clinical trial data from IMCgp100 Phase I/IIa study at AACR 2015

Immunocore reports clinical trial data from IMCgp100 Phase I/IIa study at AACR 2015

UNM Cancer Center enrolls first patient in phase 3 international clinical trial for kidney cancer vaccine

UNM Cancer Center enrolls first patient in phase 3 international clinical trial for kidney cancer vaccine

New drug combination shows promise in patients with metastatic melanoma

New drug combination shows promise in patients with metastatic melanoma

Pembrolizumab drug halts tumor growth in 76% of patients with pleural mesothelioma

Pembrolizumab drug halts tumor growth in 76% of patients with pleural mesothelioma

Penn professor to be recognized with AACR-CRI Lloyd J. Old Award in Cancer Immunology

Penn professor to be recognized with AACR-CRI Lloyd J. Old Award in Cancer Immunology

Researchers explore benefits and risks of biosimilar antibodies

Researchers explore benefits and risks of biosimilar antibodies

James Allison to be honored with 2015 Pezcoller Foundation-AACR International Award for Cancer Research

James Allison to be honored with 2015 Pezcoller Foundation-AACR International Award for Cancer Research

CiRA, Takeda collaborate to develop clinical applications of iPS cells

CiRA, Takeda collaborate to develop clinical applications of iPS cells

Obesity in African-American men increases prostate cancer risk

Obesity in African-American men increases prostate cancer risk

Yale University launches clinical study to evaluate personalized medicine for metastatic melanoma

Yale University launches clinical study to evaluate personalized medicine for metastatic melanoma

Experts to make roadmap for future research, clinical trials for SCLC patients at IASLC workshop

Experts to make roadmap for future research, clinical trials for SCLC patients at IASLC workshop

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.